← Can-Fite BioPharma Ltd.

Annual Trend FY 2016 FY 2017 FY 2018 FY 2019 FY 2020 FY 2021 FY 2022 FY 2023 FY 2024 FY 2025
ASSETS
Current assets:
Cash and Cash Equivalents, at Carrying Value $9.0m $3.5m $3.6m $2.7m $8.3m $4.4m $3.0m $4.3m $4.8m $5.5m
Accounts Receivable — — — — — — — — $0 —
Prepaid Expense and Other Assets, Current — — — — $1.1m $929k $1.2m $986k $1.1m $900k
Cash, Cash Equivalents, and Short-term Investments — — — — — — — $8.9m $7.9m —
Short-term Investments — — $273k $64k $75k $237k $8k $19k $5k $1k
Prepaid expenses, and other current assets — — — $4.4m $1.1m $929k $1.2m $986k $1.1m $900k
Assets, Current — — — $7.1m $9.4m $20.1m $9.2m $9.9m $9.0m $9.4m
Total current assets $38.9m $6.9m $7.9m $7.1m $9.4m $20.1m $9.2m $9.9m $9.0m $9.4m
Property, Plant and Equipment, Net $205k $46k $47k $36k $50k $47k $42k $29k $27k $5k
Operating Lease, Right-of-Use Asset — — — $82k $73k $138k $84k $52k $111k $69k
Operating lease right of use assets — — — $82k $73k $138k $84k $52k $111k $69k
Additional Financial Items
Issued Capital $1.8m $2.1m $2.6m $8.2m — — — — — —
Short-term deposits — — — — — $14.5m $5.0m $4.6m $3.1m $3.0m
Trade payables — — — $2.2m $561k $954k $896k $427k $618k $1.2m
Ordinary shares of no par value - Authorized: 14,000,000 and 3,333,334 shares at December 31, 2025 and 2024, respectively; Issued and outstanding: 2,618,425 and 994,394 shares as of December 31, 2025 and 2024, respectively — — — 8.2m 33.0m 60.7m — — — —
Accrued Liabilities, Current — — — $445k — — — — $301k —
Total non-current assets — — — $1.0m $123k $185k $126k $81k $138k $74k
Total non-current liabilities — — — $2.5m $2.2m $3.1m $2.3m $1.7m $1.6m $1.2m
Total shareholders’ equity — — — $2.4m $6.1m $14.4m $4.5m $6.2m $5.4m $5.6m
Assets $10.2m $7.6m $8.0m $8.2m $9.5m $20.3m $9.3m $10.0m $9.1m $9.5m
Total assets $39.1m $7.9m $8.0m $8.2m $9.5m $20.3m $9.3m $10.0m $9.1m $9.5m
LIABILITIES AND EQUITY
Current liabilities:
Operating Lease, Liability, Current — — — $36k $43k $53k $48k $27k $53k $56k
Operating Lease, Liability, Noncurrent — — — $39k $24k $71k $14k $13k $51k $15k
Deferred Revenue, Current $4.5m $959k $1.8m $2.4m $334k $818k $783k $1.7m $1.6m $1.2m
Deferred Revenue, Noncurrent $4.5m $959k $1.8m $2.4m $2.2m $3.1m $2.3m $1.7m $1.6m $1.2m
Current maturity of operating lease liability — — — $36k $43k $53k $48k $27k $53k $56k
Other accounts payable $3.6m $1.0m $1.1m $610k $331k $905k $775k $944k $976k $1.1m
Liabilities, Current — — — $3.3m $1.3m $2.7m $2.5m $2.0m $2.1m $2.7m
Total current liabilities $9.6m $1.8m $3.1m $3.3m $1.3m $2.7m $2.5m $2.0m $2.1m $2.7m
Long-term operating lease liability — — — $39k $24k $71k $14k $13k $51k $15k
Stockholders’ equity:
Common Stock, Value, Issued — — — $8.2m $33.0m $60.7m — — — —
Additional Paid in Capital $332.9m $100.3m $81.7m $103.4m $97.4m $93.3m $154.2m $163.6m $170.7m $180.7m
Retained Earnings (Accumulated Deficit) — ($93.7m) ($100.6m) ($110.3m) ($125.5m) ($140.7m) ($150.8m) ($158.5m) ($166.4m) ($176.2m)
Accumulated Other Comprehensive Income (Loss), Net of Tax ($883k) $1.1m $1.1m $1.1m $1.1m $1.1m $1.1m $1.1m $1.1m $1.1m
Additional Paid in Capital, Common Stock — — — — — — $500 — $170.7m $180.7m
Stockholders' Equity Attributable to Parent — — — $2.4m $6.1m $14.4m $4.5m $6.2m $5.4m $5.6m
Noncontrolling Interests $42k — — — — — — — — —
Liabilities and Equity — — — $8.2m $9.5m $20.3m $9.3m $10.0m $9.1m $9.5m
Total liabilities and shareholders’ equity — — — $8.2m $9.5m $20.3m $9.3m $10.0m $9.1m $9.5m

Amounts are shown in USD as reported in each fiscal year filing.